Fineotex Chem (FCL)
CyclicalFairStock Score: 46/100 — MIXED
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹43.36 |
| Market Cap | ₹5,049.28 Cr |
| P/E Ratio | 105.76 |
| ROCE | 23.76% |
| ROE | 15.28% |
| Dividend Yield | 0.37% |
| Profit Growth | 88.1% |
| Debt/Equity | 0.01 |
| Sales Growth | 174.8% |
| Promoter Holding | 62.3% |
| 52-Week Range | ₹19.1 — ₹62.44 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹10.61 |
Strengths
- Zero debt (D/E 0.00), giving a clean balance sheet in a capital-intensive industry
- ROCE of 23.76% and ROE of 15.28% show respectable capital efficiency without leverage
- Sales growth of 45.89% indicates strong demand for its specialty chemicals
- Promoter holding of 62.30% aligns owners with minority shareholders
Concerns
- Net profit fell 4.63% despite 45.89% sales growth, implying margin compression
- P/E of 28.31 and P/B of 4.53 are rich for a business with declining earnings
- Piotroski F-Score of 4/9 points to weak financial quality
- Dividend yield of 0.34% provides negligible downside protection
AI Analysis
Fineotex Chem is not the kind of business I would buy sight unseen. Let me start with what I like: zero debt, ROCE of 23.76%, and promoter holding of 62.30%. In specialty chemicals, that capital discipline matters. A company earning nearly 24% on capital without leverage has an underlying business that creates value. Book value is ₹5.12, and the balance sheet is clean. But the rest of the story gives me pause. Sales grew 45.89%, yet net profit fell 4.63%. That divergence is a red flag. For a Buffett-style investor, earnings are the engine; when revenue grows but profit does not, pricing power is missing or costs are out of control. The Piotroski F-Score is only 4/9, so financial health is mediocre, not excellent. At ₹23.19, the price is near the 52-week low of ₹19.10 and far below the high of ₹47.13. A falling knife can be a bargain, but only if fundamentals confirm recovery. At P/E of 28.31 and P/B of 4.53, this is not cheap for a company whose profit is shrinking. Dividend yield of 0.34% gives almost no support while you wait. The PEG ratio of 0.62 is misleading because it uses the 45.89% sales growth; with negative profit growth, sales growth is not translating into owner earnings. Graham would demand a margin of safety. At 28 times earnings with shrinking profits, I see risk, not reward. I would wait for evidence that profit growth returns and margins stabilise before calling this a compounding machine.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer